



## **EDAP to Highlight Its Technology At 23rd Annual European Association of Urology Congress, Milan, Italy**

### **Launch of Ablatherm-HIFU Patient Database '@-REGISTRY'**

LYON, France, March 19, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will showcase Ablatherm-HIFU and its next generation Sonolith I-sys device at the European Association of Urology (EAU) Congress, March 26-29 in Milan, Italy. EDAP's products will be on display at Booth D11.

In recent years, the EAU has grown and developed into a leading and dynamic force in urology. A thorough discussion and critical evaluation of the latest advancements in urology are key features of the scientific program. The sessions, which will include educational courses, state-of-the-art lectures, panel and round table discussions and symposia, will also provide an opportunity for all urologists to exchange views on current issues. Ablatherm-HIFU experts will have the opportunity to present their results and share their experience with other urologists.

On March 26-27, during the EAU congress, live demonstrations of Ablatherm treatments will be performed at San Gerardo Hospital, Monza, and Colombus Clinica, Milan. Urologists are invited to register and attend treatments and openly discuss the technology and its outcomes with physician users. The EAU congress will provide a unique forum for peer-to-peer interactions among urologists highlighting Ablatherm-HIFU's proven technology.

EDAP will also present its new Ablatherm Treatment "@-REGISTRY<sup>®</sup>" program, a centralized database that will compile all outcomes for patients who have undergone Ablatherm-HIFU treatment. Its unique goal is to further establish the role of HIFU and to collect data from institutions in several countries. The program will strengthen the demonstration of the long-term effectiveness of primary and salvage HIFU treatment, the strong efficacy and safety data already established at luminary centers, and the effect of different treatment parameters on Ablatherm outcomes.

John Rewcastle, Medical Director, commented, "The launching of "@-REGISTRY" Program represents a significant step forward for HIFU and is a corner stone of EDAP's global clinical research strategy. Outcomes already published by luminary European sites have established the safety and efficacy of Ablatherm-HIFU. Using "@-REGISTRY" database, it will be possible to collect and analyze data from many more centers, including data from patients already treated as well as prospectively collected patient data. Resulting publications will be used to solidify and further define the role of HIFU in the modern urology practice. It will be the leading source of data for publications regarding prostate HIFU."

Marc Oczachowski, EDAP's Chief Executive Officer, said, "The EAU Congress is the premier industry event focused on the treatment of urology, and as such, offers a tremendous forum to showcase our products to potential users. We look forward to presenting our unique @-REGISTRY database as it is a tremendous tool for physicians and the scientific community to assess HIFU treatment outcomes. As in past years, EDAP will have a strong presence at EAU and will be very visible in the congress's scientific program as HIFU continues to emerge as the standard of care for the treatment of localized prostate cancer.

#### About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit <http://www.edap-tms.com> and <http://www.hifu-planet.com> or <http://www.urotoday.com/HIFU>.

CONTACT: EDAP TMS SA  
Blandine Confort  
Investor Relations / Legal Affairs

+33 4 72 15 31 72  
bconfort@edap-tms.com

The Ruth Group  
Investors:  
Stephanie Carrington  
646-536-7017  
scarrington@theruthgroup.com

R.J. Pellegrino  
646-536-7009  
rpellegrino@theruthgroup.com